Home > Research > Publications & Outputs > Tunable emissive Ir(III) benzimidazole-quinolin...

Links

Text available via DOI:

View graph of relations

Tunable emissive Ir(III) benzimidazole-quinoline hybrids as promising theranostic lead compounds

Research output: Contribution to Journal/MagazineJournal articlepeer-review

E-pub ahead of print
  • Marta Redrado
  • Miriam Miñana
  • Michael Coogan
  • M. Concepción Gimeno
  • Vanesa Fernández-Moreira
Close
<mark>Journal publication date</mark>13/07/2022
<mark>Journal</mark>ChemMedChem
Publication StatusE-pub ahead of print
Early online date13/07/22
<mark>Original language</mark>English

Abstract

Bioactive and luminescent cyclometallated Ir(III) complexes [Ir(ppy) 2 L1 ]Cl ( 1 ) and [Ir(ppy) 2 L2 ]Cl ( 2 ) containing a benzimidazole derivative ( L1 / L2 ) as auxiliary mimic of a nucleotide have been synthesised. The emissive properties of both complexes are conditioned by the nature of L1 and L2 , rendering an orange and a green emitter respectively. Both are highly emissive with quantum yield increasing in absence of oxygen up to 0.26 ( 1 ) and 0.36 ( 2 ), suggesting their phosphorescent character. Antiproliferative activity against lung cancer A549 cells increased up to 15 times upon irradiation conditions, reaching IC 50 values in the nanomolar range (0.3 ± 0.09 μM ( 1 ) and 0.26 ± 0.14 μM ( 2 )) and pointing them as good PSs candidates for photodynamic therapy via 1 O 2 generation. Cellular biodistribution analysis by fluorescence microscopy suggest the lysosomes as the preferential accumulation organelle. Time-resolved studies showed a greatly increased cellular emission lifetime compared to the solution values, indicating binding to macromolecules or cellular structures and restriction of collision and vibrational quenching.